A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its ...
Regeneron CEO Leonard Schleifer reflects on America's tradition of innovation and explains how 250-year-old constitutional ...
Parabilis Medicines (PBLS) stock surges as Regeneron (REGN)-backed cancer drug developer makes trading debut. Read more here.
Zacks Investment Research on MSN
Here's why Regeneron (REGN) is a strong value stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Regeneron Pharmaceuticals draws attention as biotech execution, pipeline progress, and healthcare demand remain central ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks to buy with highest upside potential.
The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement ...
Regeneron's EYLEA HD US sales surged 52% in Q1 2026, offsetting competitive pressures and patient switching within the EYLEA ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare disease pipelines will be presented at two major ...
The drugmaker's fianlimab-cemiplimab combination did not reach statistical significance in improving progression-free survival (PFS).
Shares tumbled premarket after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.
Regeneron Pharmaceuticals, Inc. REGN reported first-quarter 2026 adjusted earnings per share (EPS) of $9.47, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results